- Home
- CGTX vs ICCM Comparison
CGTX vs ICCM Comparison
Compare CGTX & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- ICCM
- Stock Information
- Founded
- CGTX 2007
- ICCM 2006
- Country
- CGTX United States
- ICCM Israel
- Employees
- CGTX N/A
- ICCM N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- ICCM
- Sector
- CGTX Health Care
- ICCM
- Exchange
- CGTX Nasdaq
- ICCM Nasdaq
- Market Cap
- CGTX 53.4M
- ICCM 61.1M
- IPO Year
- CGTX 2021
- ICCM N/A
- Fundamental
- Price
- CGTX $1.54
- ICCM $0.90
- Analyst Decision
- CGTX Strong Buy
- ICCM Strong Buy
- Analyst Count
- CGTX 3
- ICCM 1
- Target Price
- CGTX $2.83
- ICCM $2.00
- AVG Volume (30 Days)
- CGTX 8.5M
- ICCM 2.8M
- Earning Date
- CGTX 08-07-2025
- ICCM 08-13-2025
- Dividend Yield
- CGTX N/A
- ICCM N/A
- EPS Growth
- CGTX N/A
- ICCM N/A
- EPS
- CGTX N/A
- ICCM N/A
- Revenue
- CGTX N/A
- ICCM $2,787,000.00
- Revenue This Year
- CGTX N/A
- ICCM $75.27
- Revenue Next Year
- CGTX N/A
- ICCM $129.39
- P/E Ratio
- CGTX N/A
- ICCM N/A
- Revenue Growth
- CGTX N/A
- ICCM N/A
- 52 Week Low
- CGTX $0.22
- ICCM $0.48
- 52 Week High
- CGTX $1.97
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- CGTX 77.80
- ICCM 44.94
- Support Level
- CGTX $1.15
- ICCM $0.70
- Resistance Level
- CGTX $0.74
- ICCM $0.86
- Average True Range (ATR)
- CGTX 0.19
- ICCM 0.06
- MACD
- CGTX 0.09
- ICCM -0.01
- Stochastic Oscillator
- CGTX 69.59
- ICCM 53.74
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.